文献速递泌尿生殖MR

PI-RADS 2.1版用于前列腺MRI解读:研究质量与癌症检测指标的相关性——系统综述与Meta分析

PI-RADS Version 2.1 for Prostate MRI Interpretation: Associations of Study Quality and Cancer Detection Metrics-A Systematic Review and Meta-Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2026-02-11

该系统综述与Meta分析纳入117项研究、25228例患者和15553个病灶,汇总PI-RADS 2.1版检测临床显著前列腺癌的敏感度、特异度及癌症检出率,并按研究质量分层。所有研究至少一个领域存在偏倚风险或适用性担忧,29%的研究为高偏倚风险或高适用性担忧;高偏倚风险研究病灶水平PI-RADS≥4的敏感度低于其余研究(78% vs 89%,p=.008),患者水平PI-RADS 2的癌症检出率高于其余研究(15% vs 4%,p=.04)。

要点

  • PI-RADS≥3患者水平敏感度96%、特异度43%;≥4敏感度88%、特异度66%。
  • 病灶水平PI-RADS≥4敏感度在高偏倚风险研究为78%,低于其余研究的89%(p=.008)。
  • PI-RADS 2的癌症检出率高偏倚风险研究为15%,高于其余研究的4%(p=.04)。

核心结论

  • 更新的汇总估计证实PI-RADS 2.1版检测临床显著前列腺癌总体敏感度高。
  • 相当比例的研究存在高偏倚风险或适用性担忧,此类研究与PI-RADS≥4敏感度降低及PI-RADS 2癌症检出率升高相关。
  • 存在质量问题研究可能产生有缺陷的性能估计。

研究设计与样本

  • 系统综述与Meta分析,检索七个数据库和注册库,检索时间为2019年3月1日至2023年9月16日。
  • 纳入117项研究,共25228例患者和15553个病灶,对象为疑似前列腺癌男性。
  • 采用QUADAS-2工具分别从四个领域和三个领域评价偏倚风险与适用性担忧。
  • 敏感度和特异度汇总估计采用双变量二项模型,癌症检出率采用随机截距logistic回归模型。

诊断标准与关键数值

  • 患者水平PI-RADS≥3的敏感度96%、特异度43%;PI-RADS≥4的敏感度88%、特异度66%。
  • 病灶水平PI-RADS≥3的敏感度96%、特异度44%;PI-RADS≥4的敏感度89%、特异度63%。
  • 患者水平癌症检出率:PI-RADS 1为3%、2为6%、3为20%、4为53%、5为83%。
  • 病灶水平PI-RADS≥4敏感度:高偏倚风险研究78% vs 其余研究89%(p=.008)。
  • 患者水平PI-RADS 2癌症检出率:高偏倚风险研究15% vs 其余研究4%(p=.04)。

临床应用与阅片要点

  • 阅读前列腺MRI报告时需注意,PI-RADS 2.1版汇总敏感度高但特异度有限,PI-RADS≥3特异度仅43%。
  • 引用PI-RADS 2.1版诊断性能数据时应考虑研究质量,高偏倚风险研究可能低估敏感度并高估PI-RADS 2的癌症检出率。

局限性

  • 所有研究至少一个领域被评为不明确或高偏倚风险或适用性担忧。
  • 29%(34/117)的研究被评为高偏倚风险或高适用性担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Estimates of outcome metrics for PI-RADS version 2.1 (v2.1) have shown substantial heterogeneity, possibly relating to risks of bias in the relevant literature. OBJECTIVE. The purpose of this study was to provide updated summary estimates for diagnostic test accuracy metrics and cancer detection rates (CDRs) of PI-RADS v2.1 for clinically significant prostate cancer (csPCa) detection and to stratify these results by study quality. EVIDENCE ACQUISITION. We searched seven databases and registers from March 1, 2019, through September 16, 2023, for studies reporting diagnostic test accuracy metrics and/or CDRs of PI-RADS v2.1 for csPCa detection in men with suspicion for prostate cancer. Studies' risk of bias and concerns of applicability were rated in four and three domains, respectively, using the QUADAS-2 tool. Summary estimates of sensitivity and specificity were derived using bivariate binomial models and of CDRs with random intercept logistic regression models. EVIDENCE SYNTHESIS. The analysis included 117 studies with 25,228 patients and 15,553 lesions. At least one domain was rated as unclear or high risk of bias or concerns of applicability in all studies and as high risk of bias or concerns of applicability in 29% (34/117) of studies. Patient-level sensitivity and specificity for PI-RADS category 3 and greater were 96% and 43% and for PI-RADS category 4 and greater were 88% and 66%, respectively. Lesion-level sensitivity and specificity for PI-RADS category 3 and greater were 96% and 44% and for PI-RADS 4 and greater were 89% and 63%, respectively. Lesion-level sensitivity for PI-RADS category 4 and greater was lower for high-risk studies than for remaining studies (78% vs 89%, p = .008). Patient-level CDR for PI-RADS categories 1, 2, 3, 4, and 5 were 3%, 6%, 20%, 53%, and 83%, respectively; CDR for PI-RADS category 2 was higher for high-risk studies than for remaining studies (15% vs 4%, p = .04). Other associations between study quality and outcome metrics were not significant (p > .05). CONCLUSION. The updated summary estimates confirm overall high sensitivity of PI-RADS v2.1 for csPCa detection. A considerable proportion of studies had high risk of bias or concerns of applicability; such studies were associated with reduced sensitivity and increased CDR for PI-RADS category 2. CLINICAL IMPACT. Studies with quality issues may yield flawed performance estimates.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Nedelcu A, Oerther B, Benkendorff A, et al. PI-RADS Version 2.1 for Prostate MRI Interpretation: Associations of Study Quality and Cancer Detection Metrics-A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2026. PMID: 41090646. doi:10.2214/AJR.25.33583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。